ArticleCirculation research2021
Growth Arrest Specific-6 and Axl Coordinate Inflammation and Hypertension.
Open access · bronzeAbstract read
In one paragraph
Article in Circulation research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Molecular mechanisms, therapeutic strategies, and inter-organ fibrosis crosstalk of Gla proteins in cardiovascular disease.Communications biology · 2026Review
- Inhibition of AXL receptor tyrosine kinase increases osteoblast function and bone mass.Bone research · 2026Article
- Innate immunity and hypertension: unveiling inflammatory pathways for novel therapies.Frontiers in pharmacology · 2026Review
- Inhibition of Axl attenuates acute kidney injury by alleviating inflammation via SOCS3 downregulation in tubular epithelial cells.BMC nephrology · 2025Article
- Recent advances on immunity and hypertension: the new cells on the kidney block.American journal of physiology. Renal physiology · 2025Review
- Functions of TAM Receptors and Ligands Protein S and Gas6 in Atherosclerosis and Cardiovascular Disease.International journal of molecular sciences · 2024Review
- Posttranslationally modified self-peptides promote hypertension in mouse models.The Journal of clinical investigation · 2024Article
- Immunological insights into hypertension: unraveling triggers and potential therapeutic avenues.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- Immune mechanisms in the pathophysiology of hypertension.Nature reviews. Nephrology · 2024Review
- Immune Mechanisms in Hypertension.Hypertension (Dallas, Tex. : 1979) · 2024Review
- Innovative assessment of lipid-induced oxidative stress and inflammation in harvested human endothelial cells.Physiological reports · 2024Article
- NETosis Drives Blood Pressure Elevation and Vascular Dysfunction in Hypertension.Circulation research · 2024Article
- Immunoproteasomal Processing of IsoLG-Adducted Proteins Is Essential for Hypertension.Circulation research · 2024Article
- Network medicine: an approach to complex kidney disease phenotypes.Nature reviews. Nephrology · 2023Review
- Endothelial mechanical stretch regulates the immunological synapse interface of renal endothelial cells in a sex-dependent manner.American journal of physiology. Renal physiology · 2023Article
- Endothelial Cell Dysfunction and Increased Cardiovascular Risk in Patients With Chronic Kidney Disease.Circulation research · 2023Review
- Prognostic value of plasma sAXL in patients with heart failure: insights from the DRAGON-HF trial.ESC heart failure · 2023Observational
- Plasma GAS6 predicts mortality risk in acute heart failure patients: insights from the DRAGON-HF trial.Journal of translational medicine · 2023Observational
- Axl promotes intracranial aneurysm rupture by regulating macrophage polarization toward M1Frontiers in immunology · 2023Article
- Role of Axl in target organ inflammation and damage due to hypertensive aortic remodeling.American journal of physiology. Heart and circulatory physiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Justin P Van BeusecumDivison of Clinical Pharmacology, Department of Medicine (J.P.V.B., N.R.B., D.M.P., N.d.l.V., M.A., L.X., C.A.S., D.G.H.), Vanderbilt University Medical Center, Nashville, TN.
Natalia R BarbaroDivison of Clinical Pharmacology, Department of Medicine (J.P.V.B., N.R.B., D.M.P., N.d.l.V., M.A., L.X., C.A.S., D.G.H.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-1596-1085
Charles D SmartDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN (C.D.S., D.G.H.).
David M PatrickDivison of Clinical Pharmacology, Department of Medicine (J.P.V.B., N.R.B., D.M.P., N.d.l.V., M.A., L.X., C.A.S., D.G.H.), Vanderbilt University Medical Center, Nashville, TN.
Roxana LoperenaVanderbilt Institute of Clinical and Translational Research (R.L.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-4783-3291
Shilin ZhaoVanderbilt Center for Quantitative Sciences (S.Z.), Vanderbilt University Medical Center, Nashville, TN.
Nestor de la VisitacionDivison of Clinical Pharmacology, Department of Medicine (J.P.V.B., N.R.B., D.M.P., N.d.l.V., M.A., L.X., C.A.S., D.G.H.), Vanderbilt University Medical Center, Nashville, TN.
Mingfang AoDivison of Clinical Pharmacology, Department of Medicine (J.P.V.B., N.R.B., D.M.P., N.d.l.V., M.A., L.X., C.A.S., D.G.H.), Vanderbilt University Medical Center, Nashville, TN.
Liang XiaoDivison of Clinical Pharmacology, Department of Medicine (J.P.V.B., N.R.B., D.M.P., N.d.l.V., M.A., L.X., C.A.S., D.G.H.), Vanderbilt University Medical Center, Nashville, TN.
Cyndya A ShibaoDivison of Clinical Pharmacology, Department of Medicine (J.P.V.B., N.R.B., D.M.P., N.d.l.V., M.A., L.X., C.A.S., D.G.H.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-4518-6801
David G HarrisonDivison of Clinical Pharmacology, Department of Medicine (J.P.V.B., N.R.B., D.M.P., N.d.l.V., M.A., L.X., C.A.S., D.G.H.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0001-9363-6451
Vanderbilt University Medical Center · USVanderbilt University · US
Funding
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3MThe Role of Inflammation in Cardiovascular DiseaseP01HL129941 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARRISON, DAVID G · 2016 to 2020
$12.4MCLINICAL PHARMACOLOGY TRAINING PROGRAMT32GM007569 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Bjorn C Knollmann · 1985 to 2026
$12.4MMechanisms of Immune Activation in HypertensionR35HL140016 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARRISON, DAVID G · 2018 to 2024
$5.3MMedical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8MROLE OF CD36 IN NUTRIENT DELIVERY AND ITS DYSFUNCTION IN AFRICAN AMERICANSR01DK111175 · NIDDK · WASHINGTON UNIVERSITY · PI ABUMRAD, NADA A., ABUMRAD, NAJI N · 2016 to 2019
$1.9MVanderbilt Hypertension and Blood Pressure Regulation ProgramT32HL144446 · NHLBI · VANDERBILT UNIVERSITY · PI HARRISON, DAVID G · 2019 to 2023
$1.7MA Role of Isolevuglandin Adducts in Essential Hypertension and Systemic Lupus ErythematosusK08HL153789 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PATRICK, DAVID · 2020 to 2021
$317kInterleukin-21 and endothelial dysfunction in hypertensionF30HL151069 · NHLBI · VANDERBILT UNIVERSITY · PI SMART, CHARLES DUNCAN · 2020 to 2023
$140kThe role of salt and SGK1 on NADPH oxidase stabilization in dendritic cells in hypertensionF32HL143927 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI VAN BEUSECUM, JUSTIN PIETER · 2019 to 2020
$120kIsolevuglandin peptide modification and proteasomal processing is responsible for autoimmune mediated hypertensionF32HL144050 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PATRICK, DAVID · 2019 to 2019
$70kBLRD VA IK2 BX005376BLRD VA IK2 BX005605NCATS NIH HHS UL1 TR002243NHLBI NIH HHS F30 HL151069NHLBI NIH HHS F32 HL143927NHLBI NIH HHS F32 HL144050NHLBI NIH HHS K08 HL153789NHLBI NIH HHS P01 HL129941NHLBI NIH HHS R35 HL140016NHLBI NIH HHS T32 HL144446NIDDK NIH HHS R01 DK111175NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32 GM007569NIGMS NIH HHS T32 GM152284
Abstract
[Figure: see text].
Indexed as
AdultAgedAngiotensin IIAnimalsAxl Receptor Tyrosine KinaseCells, CulturedDendritic CellsEndothelial CellsFemaleGrowth Arrest-Specific Protein 6HumansHypertensionIntercellular Adhesion Molecule-1Intercellular Signaling Peptides and ProteinsInterleukin-1betaMaleAngiotensin IIAxl Receptor Tyrosine KinaseGrowth Arrest-Specific Protein 6Intercellular Adhesion Molecule-1Intercellular Signaling Peptides and ProteinsInterleukin-1betaNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanProto-Oncogene ProteinsReceptor Protein-Tyrosine Kinasesblood pressurehypertensioninflammationmacrophagesplasma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.